GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroPort NeuroTech Ltd (HKSE:02172) » Definitions » Cash Ratio

MicroPort NeuroTech (HKSE:02172) Cash Ratio : 4.03 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is MicroPort NeuroTech Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. MicroPort NeuroTech's Cash Ratio for the quarter that ended in Dec. 2023 was 4.03.

MicroPort NeuroTech has a Cash Ratio of 4.03. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for MicroPort NeuroTech's Cash Ratio or its related term are showing as below:

HKSE:02172' s Cash Ratio Range Over the Past 10 Years
Min: 0.15   Med: 4.03   Max: 4.49
Current: 4.03

During the past 5 years, MicroPort NeuroTech's highest Cash Ratio was 4.49. The lowest was 0.15. And the median was 4.03.

HKSE:02172's Cash Ratio is ranked better than
79.91% of 856 companies
in the Medical Devices & Instruments industry
Industry Median: 1.2 vs HKSE:02172: 4.03

MicroPort NeuroTech Cash Ratio Historical Data

The historical data trend for MicroPort NeuroTech's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MicroPort NeuroTech Cash Ratio Chart

MicroPort NeuroTech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
0.15 4.49 3.41 4.49 4.03

MicroPort NeuroTech Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial 3.41 3.18 4.49 4.73 4.03

Competitive Comparison of MicroPort NeuroTech's Cash Ratio

For the Medical Devices subindustry, MicroPort NeuroTech's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MicroPort NeuroTech's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MicroPort NeuroTech's Cash Ratio distribution charts can be found below:

* The bar in red indicates where MicroPort NeuroTech's Cash Ratio falls into.



MicroPort NeuroTech Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

MicroPort NeuroTech's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1098.897/272.623
=4.03

MicroPort NeuroTech's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1098.897/272.623
=4.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MicroPort NeuroTech  (HKSE:02172) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


MicroPort NeuroTech Cash Ratio Related Terms

Thank you for viewing the detailed overview of MicroPort NeuroTech's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MicroPort NeuroTech (HKSE:02172) Business Description

Traded in Other Exchanges
N/A
Address
No. 1661 Zhangdong Road, Pudong New Area, Shanghai, CHN
MicroPort NeuroTech Ltd is into the neuro-interventional medical device industry, dedicated to providing innovative solutions for physicians and patients. The company boast a comprehensive portfolio of approved therapeutic products covering all of the three main areas of neurovascular disease, namely hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke.
Executives
Hu Yibin
Biolink Biomedical Ltd. 2201 Interest of corporation controlled by you
Blossom Vision Limited 2201 Interest of corporation controlled by you
Lion Fish Limited 2201 Interest of corporation controlled by you
Suntera Corporate Trustees (hong Kong) Limited 2301 Trustee
Thriving Hope Limited 2201 Interest of corporation controlled by you
Biolink Fund Limited Partnership 2201 Interest of corporation controlled by you
Biolink Limited 2101 Beneficial owner
Microport Scientific Corporation
Microport Scientific Investment Ltd
Maxwell Maxcare Science Foundation Limited
We'tron Capital Limited

MicroPort NeuroTech (HKSE:02172) Headlines

No Headlines